A panel deliberates post-neoadjuvant strategies and data requirements for optimizing immune checkpoint inhibitors in NSCLC neoadjuvant therapy.
Related Keywords
Spain ,David Carbone ,Martin Dietrich ,Patrick Forde , ,Nsclc ,Non Small Cell Lung Cancer ,Neoadjuvant ,Advanced Disease ,Early Stage Disease ,Post Op Setting ,Novel Agent ,Targeted Therapy ,Immunotherapy ,Trio Therapy ,
comparemela.com © 2020. All Rights Reserved.